Advanced search
Publication Cover
Future Medicinal Chemistry Volume 16, 2024 - Issue 4
Submit an article Journal homepage
173
Views
0
CrossRef citations to date
0
Altmetric
Review

Molecules Inducing Specific Cyclin-Dependent Kinase Degradation and their Possible Use in Cancer Therapy

Mingming Zheng1 State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China;2 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China
,
Xiao-Yu Zhang1 State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China;2 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China
,
Weijiao Chen1 State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China;2 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China
,
Fei Xia1 State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China;2 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China
,
Huanaoyu Yang1 State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China;2 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China
,
Kai Yuan1 State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China;2 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, ChinaCorrespondence[email protected]
&
Peng Yang1 State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China;2 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China;3 Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing, 211198, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2613-941X
ORCID Icon show all
Pages 369-388 | Received 01 Sep 2023, Accepted 12 Jan 2024, Published online: 30 Jan 2024

References

  • Canavese M , Santo L , Raje N . Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol. Ther. 13(7), 451–457 (2012).
  • Zhang M , Zhang L , Hei R et al. CDK inhibitors in cancer therapy, an overview of recent development. Am. J. Cancer Res. 11(5), 1913–1935 (2021).
  • Meijer L , Borgne A , Mulner O et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243(1–2), 527–536 (1997).
  • Whittaker SR , Mallinger A , Workman P , Clarke PA . Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol. Ther. 173, 83–105 (2017).
  • Fry DW , Harvey PJ , Keller PR et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3(11), 1427–1438 (2004).
  • Gelbert LM , Cai S , Lin X et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest. New Drugs 32(5), 825–837 (2014).
  • Tripathy D , Bardia A , Sellers WR . Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin. Cancer Res. 23(13), 3251–3262 (2017).
  • Adon T , Shanmugarajan D , Kumar HY . CDK4/6 inhibitors: a brief overview and prospective research directions. RSC Adv. 11(47), 29227–29246 (2021).
  • Pandey K , An HJ , Kim SK et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review. Int. J. Cancer 145(5), 1179–1188 (2019).
  • Álvarez-Fernández M , Malumbres M . Mechanisms of sensitivity and resistance to CDK4/6 inhibition. Cancer Cell 37(4), 514–529 (2020).
  • Li Z , Razavi P , Li Q et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway. Cancer Cell 34(6), 893–905.e898 (2018).
  • Eyre TA , Riches JC . The evolution of therapies targeting Bruton tyrosine kinase for the treatment of chronic lymphocytic leukaemia: future perspectives. Cancers (Basel) 15(9), 2596 (2023).
  • Surka C , Jin L , Mbong N et al. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood 137(5), 661–677 (2021).
  • Chirnomas D , Hornberger KR , Crews CM . Protein degraders enter the clinic – a new approach to cancer therapy. Nat. Rev. Clin. Oncol. 20(4), 265–278 (2023).
  • Duronio RJ , Xiong Y . Signaling pathways that control cell proliferation. Cold Spring Harb. Perspect. Biol. 5(3), a008904 (2013).
  • Fischer M , Schade AE , Branigan TB , Müller GA , Decaprio JA . Coordinating gene expression during the cell cycle. Trends Biochem. Sci. 47(12), 1009–1022 (2022).
  • Moreno E , Pandit SK , Toussaint MJM et al. Atypical E2Fs either counteract or cooperate with RB during tumorigenesis depending on tissue context. Cancers (Basel) 13(9), 2033 (2021).
  • Bertoli C , Skotheim JM , De Bruin RA . Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 14(8), 518–528 (2013).
  • Gao X , Leone GW , Wang H . Cyclin D–CDK4/6 functions in cancer. Adv. Cancer Res. 148, 147–169 (2020).
  • Hughes BT , Sidorova J , Swanger J , Monnat RJ Jr , Clurman BE . Essential role for Cdk2 inhibitory phosphorylation during replication stress revealed by a human Cdk2 knockin mutation. Proc. Natl Acad. Sci. USA 110(22), 8954–8959 (2013).
  • Tadesse S , Anshabo AT , Portman N et al. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov. Today 25(2), 406–413 (2020).
  • Fagundes R , Teixeira LK . Cyclin E/CDK2: DNA replication, replication stress and genomic instability. Front. Cell Dev. Biol. 9, 774845 (2021).
  • Sunada S , Saito H , Zhang D , Xu Z , Miki Y . CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity. Biochem. Biophys. Res. Commun. 550, 56–61 (2021).
  • Clark JM , Gabrielli BG . Production of a soluble cyclin B/cdc2 substrate for cdc25 phosphatase. Anal. Biochem. 254(2), 231–235 (1997).
  • Herrero-Ruiz J , Mora-Santos M , Giráldez S et al. βTrCP controls the lysosome-mediated degradation of CDK1, whose accumulation correlates with tumor malignancy. Oncotarget 5(17), 7563–7574 (2014).
  • Yoon CH , Miah MA , Kim KP , Bae YS . New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers Cdc2 polyubiquitination and G2 arrest under genotoxic stresses. EMBO Rep. 11(5), 393–399 (2010).
  • Cai Z , Wang J , Li Y et al. Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. Sci. China Life Sci. 66(1), 94–109 (2023).
  • Hsin JP , Manley JL . The RNA polymerase II CTD coordinates transcription and RNA processing. Genes Dev. 26(19), 2119–2137 (2012).
  • Sansó M , Fisher RP . Pause, play, repeat: CDKs push RNAP II’s buttons. Transcription 4(4), 146–152 (2013).
  • Chou J , Quigley DA , Robinson TM , Feng FY , Ashworth A . Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 10(3), 351–370 (2020).
  • Whelan M , Pelchat M . Role of RNA polymerase II promoter-proximal pausing in viral transcription. Viruses 14(9), 2029 (2022).
  • Allen BL , Taatjes DJ . The Mediator complex: a central integrator of transcription. Nat. Rev. Mol. Cell Biol. 16(3), 155–166 (2015).
  • Van De Peppel J , Kettelarij N , Van Bakel H , Kockelkorn TT , Van Leenen D , Holstege FC . Mediator expression profiling epistasis reveals a signal transduction pathway with antagonistic submodules and highly specific downstream targets. Mol. Cell 19(4), 511–522 (2005).
  • Holstege FC , Jennings EG , Wyrick JJ et al. Dissecting the regulatory circuitry of a eukaryotic genome. Cell 95(5), 717–728 (1998).
  • Ansari SA , Ganapathi M , Benschop JJ , Holstege FC , Wade JT , Morse RH . Distinct role of Mediator tail module in regulation of SAGA-dependent, TATA-containing genes in yeast. EMBO J. 31(1), 44–57 (2012).
  • Akoulitchev S , Chuikov S , Reinberg D . TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature 407(6800), 102–106 (2000).
  • Fant CB , Taatjes DJ . Regulatory functions of the Mediator kinases CDK8 and CDK19. Transcription 10(2), 76–90 (2019).
  • Galbraith MD , Donner AJ , Espinosa JM . CDK8: a positive regulator of transcription. Transcription 1(1), 4–12 (2010).
  • Donner AJ , Szostek S , Hoover JM , Espinosa JM . CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol. Cell. 27(1), 121–133 (2007).
  • Liu Y , Kung C , Fishburn J , Ansari AZ , Shokat KM , Hahn S . Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex. Mol. Cell. Biol. 24(4), 1721–1735 (2004).
  • Parua PK , Fisher RP . Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors. Nat. Chem. Biol. 16(7), 716–724 (2020).
  • Akhtar MS , Heidemann M , Tietjen JR et al. TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. Mol. Cell 34(3), 387–393 (2009).
  • Li ZM , Liu G , Gao Y , Zhao MG . Targeting CDK7 in oncology: the avenue forward. Pharmacol. Ther. 240, 108229 (2022).
  • Booth GT , Parua PK , Sansó M , Fisher RP , Lis JT . Cdk9 regulates a promoter-proximal checkpoint to modulate RNA polymerase II elongation rate in fission yeast. Nat. Commun. 9(1), 543 (2018).
  • Magnuson B , Bedi K , Narayanan IV et al. CDK12 regulates co-transcriptional splicing and RNA turnover in human cells. iScience 25(9), 105030 (2022).
  • Blazek D , Kohoutek J , Bartholomeeusen K et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25(20), 2158–2172 (2011).
  • Ebmeier CC , Erickson B , Allen BL et al. Human TFIIH kinase CDK7 regulates transcription-associated chromatin modifications. Cell Rep. 20(5), 1173–1186 (2017).
  • Sansó M , Levin RS , Lipp JJ et al. P-TEFb regulation of transcription termination factor Xrn2 revealed by a chemical genetic screen for Cdk9 substrates. Genes Dev. 30(1), 117–131 (2016).
  • Anshabo AT , Milne R , Wang S , Albrecht H . CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Front. Oncol. 11, 678559 (2021).
  • Davies TG , Pratt DJ , Endicott JA , Johnson LN , Noble ME . Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther. 93(2–3), 125–133 (2002).
  • Liu Y , Gray NS . Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2(7), 358–364 (2006).
  • Johnson LN . Protein kinase inhibitors: contributions from structure to clinical compounds. Q. Rev. Biophys. 42(1), 1–40 (2009).
  • Christian BA , Grever MR , Byrd JC , Lin TS . Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr. Opin. Oncol. 19(6), 573–578 (2007).
  • Criscitiello C , Viale G , Esposito A , Curigliano G . Dinaciclib for the treatment of breast cancer. Expert Opin. Investig. Drugs 23(9), 1305–1312 (2014).
  • O’leary B , Finn RS , Turner NC . Treating cancer with selective CDK4/6 inhibitors. Nat. Rev. Clin. Oncol. 13(7), 417–430 (2016).
  • Shi Z , Tian L , Qiang T et al. From structure modification to drug launch: a systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy. J. Med. Chem. 65(9), 6390–6418 (2022).
  • Constantin TA , Varela-Carver A , Greenland KK et al. The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br. J. Cancer 128(12), 2326–2337 (2023).
  • Nedelsky NB , Todd PK , Taylor JP . Autophagy and the ubiquitin–proteasome system: collaborators in neuroprotection. Biochim. Biophys. Acta 1782(12), 691–699 (2008).
  • Yang Q , Zhao J , Chen D , Wang Y . E3 ubiquitin ligases: styles, structures and functions. Mol. Biomed. 2(1), 23 (2021).
  • Troup RI , Fallan C , Baud MGJ . Current strategies for the design of PROTAC linkers: a critical review. Explor. Target. Antitumor Ther. 1(5), 273–312 (2020).
  • Zhao B , Burgess K . PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer. Chem. Commun. (Camb.) 55(18), 2704–2707 (2019).
  • Wang H , Nicolay BN , Chick JM et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature 546(7658), 426–430 (2017).
  • Tigan AS , Bellutti F , Kollmann K , Tebb G , Sexl V . CDK6 – a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene 35(24), 3083–3091 (2016).
  • Kollmann K , Heller G , Schneckenleithner C et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 24(2), 167–181 (2013).
  • Brand M , Jiang B , Bauer S et al. Homolog-selective degradation as a strategy to probe the function of CDK6 in AML. Cell Chem. Biol. 26(2), 300–306.e309 (2019).
  • Li Q , Jiang B , Guo J et al. INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. Cancer Discov. 12(2), 356–371 (2022).
  • Wei M , Zhao R , Cao Y et al. First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo . Eur. J. Med. Chem. 209, 112903 (2021).
  • Anderson NA , Cryan J , Ahmed A et al. Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs. Bioorg. Med. Chem. Lett. 30(9), 127106 (2020).
  • Steinebach C , Ng YLD , Sosič I et al. Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chem. Sci. 11(13), 3474–3486 (2020).
  • Su S , Yang Z , Gao H et al. Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders. J. Med. Chem. 62(16), 7575–7582 (2019).
  • Xiong Y , Zhong Y , Yim H et al. Bridged proteolysis targeting chimera (PROTAC) enables degradation of undruggable targets. J. Am. Chem. Soc. 144(49), 22622–22632 (2022).
  • Teng M , Jiang J , He Z et al. Development of CDK2 and CDK5 dual degrader TMX-2172. Angew. Chem. Int. Ed. Engl. 59(33), 13865–13870 (2020).
  • Zhou F , Chen L , Cao C et al. Development of selective mono or dual PROTAC degrader probe of CDK isoforms. Eur. J. Med. Chem. 187, 111952 (2020).
  • Ying M , Shao X , Jing H et al. Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood 131(24), 2698–2711 (2018).
  • Wang L , Shao X , Zhong T et al. Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nat. Chem. Biol. 17(5), 567–575 (2021).
  • Robb CM , Contreras JI , Kour S et al. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem. Commun. (Camb.) 53(54), 7577–7580 (2017).
  • Olson CM , Jiang B , Erb MA et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat. Chem. Biol. 14(2), 163–170 (2018).
  • Bian J , Ren J , Li Y et al. Discovery of wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity. Bioorg. Chem. 81, 373–381 (2018).
  • Qiu X , Li Y , Yu B et al. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion. Eur. J. Med. Chem. 211, 113091 (2021).
  • Jiang B , Gao Y , Che J et al. Discovery and resistance mechanism of a selective CDK12 degrader. Nat. Chem. Biol. 17(6), 675–683 (2021).
  • Niu T , Li K , Jiang L et al. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor. Eur. J. Med. Chem. 228, 114012 (2022).
  • Yang J , Chang Y , Tien JC et al. Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13. J. Med. Chem. 65(16), 11066–11083 (2022).
  • Koroleva OA , Dutikova YV , Trubnikov AV et al. PROTAC: targeted drug strategy. Principles and limitations. Russ. Chem. Bull. 71(11), 2310–2334 (2022).
  • Wang Y , Jiang X , Feng F , Liu W , Sun H . Degradation of proteins by PROTACs and other strategies. Acta Pharm. Sin. B 10(2), 207–238 (2020).
  • Qiu J , Bai X , Zhang W et al. LPM3770277, a potent novel CDK4/6 degrader, exerts antitumor effect against triple-negative breast cancer. Front. Pharmacol. 13, 853993 (2022).
  • Wang M , Lin R , Li J et al. Discovery of LL-K8-22: a selective, durable, and small-molecule degrader of the CDK8–cyclin C complex. J. Med. Chem. 66(7), 4932–4951 (2023).
  • Zhou K , Zhuang S , Liu F et al. Disrupting the Cdk9/Cyclin T1 heterodimer of 7SK snRNP for the Brd4 and AFF1/4 guided reconstitution of active P-TEFb. Nucleic Acids Res. 50(2), 750–762 (2022).
  • Li JC , Liu T , Song YL et al. Discovery of small-molecule degraders of the CDK9–cyclin T1 complex for targeting transcriptional addiction in prostate cancer. J. Med. Chem. 65(16), 11034–11057 (2022).
  • Stanton BZ , Chory EJ , Crabtree GR . Chemically induced proximity in biology and medicine. Science 359(6380), eaao5902 (2018).
  • Dong G , Ding Y , He S , Sheng C . Molecular glues for targeted protein degradation: from serendipity to rational discovery. J. Med. Chem. 64(15), 10606–10620 (2021).
  • Bettayeb K , Oumata N , Echalier A et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 27(44), 5797–5807 (2008).
  • Słabicki M , Kozicka Z , Petzold G et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585(7824), 293–297 (2020).
  • Lv L , Chen P , Cao L et al. Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation. Elife 9, e59994 (2020).
  • Mayor-Ruiz C , Bauer S , Brand M et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nat. Chem. Biol. 16(11), 1199–1207 (2020).
  • Jorda R , Havlíček L , Peřina M et al. 3,5,7-Substituted pyrazolo[4,3-d]pyrimidine inhibitors of cyclin-dependent kinases and cyclin K degraders. J. Med. Chem. 65(13), 8881–8896 (2022).
  • Toriki ES , Papatzimas JW , Nishikawa K et al. Rational chemical design of molecular glue degraders. ACS Cent. Sci. 9(5), 915–926 (2023).
  • Eskelinen EL , Saftig P . Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim. Biophys. Acta 1793(4), 664–673 (2009).
  • Zhang J , Gan Y , Li H et al. Inhibition of the CDK2 and cyclin A complex leads to autophagic degradation of CDK2 in cancer cells. Nat. Commun. 13(1), 2835 (2022).
  • Basset CA , Conway De Macario E , Leone LG , Macario AJL , Leone A . The chaperone system in cancer therapies: Hsp90. J. Mol. Histol. 54(2), 105–118 (2023).
  • Paladino A , Woodford MR , Backe SJ et al. Chemical perturbation of oncogenic protein folding: from the prediction of locally unstable structures to the design of disruptors of Hsp90–client interactions. Chemistry 26(43), 9459–9465 (2020).
  • Gray PJ Jr , Prince T , Cheng J , Stevenson MA , Calderwood SK . Targeting the oncogene and kinome chaperone CDC37. Nat. Rev. Cancer 8(7), 491–495 (2008).
  • Jinwal UK , Trotter JH , Abisambra JF et al. The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics. J. Biol. Chem. 286(19), 16976–16983 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.